Effect of peptidases at the blood brain barrier on the permeability of enkephalin

E. A. Brownson, T. J. Abbruscato, T. J. Gillespie, Victor J Hruby, Thomas P Davis

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

The blood brain barrier (BBB) presents an enzymatic barrier to the passage of peptides from blood to brain. The studies presented here used a well established in vitro model of the BBB to measure the presence of peptidases and the permeability of two opioid peptides. The in vitro BBB model consisted of confluent monolayers of bovine brain microvessel endothelial cells (BMECs). Enkephalin metabolizing enzymes, total aminopeptidase, aminopeptidase M (APM), angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) activities were measured in BMEC monolayers. The effect of specific inhibitors of APM, ACE and NEP on the permeability of [Met5]enkephalin (Met-Enk) and a conformationally constrained and enzymatically stable analog, DPDPE, also was determined. High levels of membrane-associated enzyme activity were measured for total aminopeptidase, APM and ACE. Interestingly, the permeability coefficient of Met-Enk was increased 4-fold in the presence of specific inhibitors of APM and ACE. Low levels of NEP activity were measured in BMEC monolayers and inhibition of NEP had no effect on Met-Enk permeability. The permeability coefficient for DPDPE was not increased with enzyme inhibitors but was 4-fold greater than Met-Enk alone. In the presence of APM or ACE inhibitors, there was no difference in the permeability of DPDPE and Met-Enk. These experiments demonstrate the presence of specific peptidases in BMECs and that the presence of inhibitors to Met-Enk inactivating peptidases significantly increased permeability of this biologically active peptide.

Original languageEnglish (US)
Pages (from-to)675-680
Number of pages6
JournalJournal of Pharmacology and Experimental Therapeutics
Volume270
Issue number2
StatePublished - 1994

Fingerprint

Enkephalins
Blood-Brain Barrier
CD13 Antigens
Permeability
Peptide Hydrolases
Neprilysin
D-Penicillamine (2,5)-Enkephalin
Peptidyl-Dipeptidase A
Microvessels
Endothelial Cells
Brain
Aminopeptidases
Peptides
Opioid Peptides
Enzyme Inhibitors
Enzymes
Angiotensin-Converting Enzyme Inhibitors
Membranes

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effect of peptidases at the blood brain barrier on the permeability of enkephalin. / Brownson, E. A.; Abbruscato, T. J.; Gillespie, T. J.; Hruby, Victor J; Davis, Thomas P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 270, No. 2, 1994, p. 675-680.

Research output: Contribution to journalArticle

@article{aa3834b94c1e4f57ad72326c4e28f5b0,
title = "Effect of peptidases at the blood brain barrier on the permeability of enkephalin",
abstract = "The blood brain barrier (BBB) presents an enzymatic barrier to the passage of peptides from blood to brain. The studies presented here used a well established in vitro model of the BBB to measure the presence of peptidases and the permeability of two opioid peptides. The in vitro BBB model consisted of confluent monolayers of bovine brain microvessel endothelial cells (BMECs). Enkephalin metabolizing enzymes, total aminopeptidase, aminopeptidase M (APM), angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) activities were measured in BMEC monolayers. The effect of specific inhibitors of APM, ACE and NEP on the permeability of [Met5]enkephalin (Met-Enk) and a conformationally constrained and enzymatically stable analog, DPDPE, also was determined. High levels of membrane-associated enzyme activity were measured for total aminopeptidase, APM and ACE. Interestingly, the permeability coefficient of Met-Enk was increased 4-fold in the presence of specific inhibitors of APM and ACE. Low levels of NEP activity were measured in BMEC monolayers and inhibition of NEP had no effect on Met-Enk permeability. The permeability coefficient for DPDPE was not increased with enzyme inhibitors but was 4-fold greater than Met-Enk alone. In the presence of APM or ACE inhibitors, there was no difference in the permeability of DPDPE and Met-Enk. These experiments demonstrate the presence of specific peptidases in BMECs and that the presence of inhibitors to Met-Enk inactivating peptidases significantly increased permeability of this biologically active peptide.",
author = "Brownson, {E. A.} and Abbruscato, {T. J.} and Gillespie, {T. J.} and Hruby, {Victor J} and Davis, {Thomas P}",
year = "1994",
language = "English (US)",
volume = "270",
pages = "675--680",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Effect of peptidases at the blood brain barrier on the permeability of enkephalin

AU - Brownson, E. A.

AU - Abbruscato, T. J.

AU - Gillespie, T. J.

AU - Hruby, Victor J

AU - Davis, Thomas P

PY - 1994

Y1 - 1994

N2 - The blood brain barrier (BBB) presents an enzymatic barrier to the passage of peptides from blood to brain. The studies presented here used a well established in vitro model of the BBB to measure the presence of peptidases and the permeability of two opioid peptides. The in vitro BBB model consisted of confluent monolayers of bovine brain microvessel endothelial cells (BMECs). Enkephalin metabolizing enzymes, total aminopeptidase, aminopeptidase M (APM), angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) activities were measured in BMEC monolayers. The effect of specific inhibitors of APM, ACE and NEP on the permeability of [Met5]enkephalin (Met-Enk) and a conformationally constrained and enzymatically stable analog, DPDPE, also was determined. High levels of membrane-associated enzyme activity were measured for total aminopeptidase, APM and ACE. Interestingly, the permeability coefficient of Met-Enk was increased 4-fold in the presence of specific inhibitors of APM and ACE. Low levels of NEP activity were measured in BMEC monolayers and inhibition of NEP had no effect on Met-Enk permeability. The permeability coefficient for DPDPE was not increased with enzyme inhibitors but was 4-fold greater than Met-Enk alone. In the presence of APM or ACE inhibitors, there was no difference in the permeability of DPDPE and Met-Enk. These experiments demonstrate the presence of specific peptidases in BMECs and that the presence of inhibitors to Met-Enk inactivating peptidases significantly increased permeability of this biologically active peptide.

AB - The blood brain barrier (BBB) presents an enzymatic barrier to the passage of peptides from blood to brain. The studies presented here used a well established in vitro model of the BBB to measure the presence of peptidases and the permeability of two opioid peptides. The in vitro BBB model consisted of confluent monolayers of bovine brain microvessel endothelial cells (BMECs). Enkephalin metabolizing enzymes, total aminopeptidase, aminopeptidase M (APM), angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) activities were measured in BMEC monolayers. The effect of specific inhibitors of APM, ACE and NEP on the permeability of [Met5]enkephalin (Met-Enk) and a conformationally constrained and enzymatically stable analog, DPDPE, also was determined. High levels of membrane-associated enzyme activity were measured for total aminopeptidase, APM and ACE. Interestingly, the permeability coefficient of Met-Enk was increased 4-fold in the presence of specific inhibitors of APM and ACE. Low levels of NEP activity were measured in BMEC monolayers and inhibition of NEP had no effect on Met-Enk permeability. The permeability coefficient for DPDPE was not increased with enzyme inhibitors but was 4-fold greater than Met-Enk alone. In the presence of APM or ACE inhibitors, there was no difference in the permeability of DPDPE and Met-Enk. These experiments demonstrate the presence of specific peptidases in BMECs and that the presence of inhibitors to Met-Enk inactivating peptidases significantly increased permeability of this biologically active peptide.

UR - http://www.scopus.com/inward/record.url?scp=0027931494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027931494&partnerID=8YFLogxK

M3 - Article

VL - 270

SP - 675

EP - 680

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -